Safety study of IBI3013 for vitiligo and hair loss
Treatments studied
Part of Skin clinical trials.
This is an early-stage safety study of a new drug called IBI3013. The trial tests how safe the drug is and how your body processes it. It enrolls healthy volunteers first, then people with vitiligo (loss of skin color) or severe alopecia areata (patchy hair loss).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are male, age 18–60 (depending on which part of the trial)
- You have either vitiligo diagnosed 3 months to 2 years ago, or severe hair loss affecting 50%+ of your scalp for 6 months to 4 years
- You agree to use effective contraception and not donate sperm for 6 months after the last injection
- You have no recent vaccines, active infections, tuberculosis, or herpes zoster history
- You are not pregnant, lactating, or dealing with unstable heart disease, stroke, or blood clots
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication called IBI3033 for people with moderate-to-severe atopic dermatitis (eczema) that hasn't improved with skin creams alone. The goal is to see if this drug can safely reduce itching, inflammation, and affected skin area.
This study tests an investigational drug (GIA632) in people with non-segmental vitiligo. It aims to see if different doses can safely and effectively restore color to white patches.
This trial tests a new treatment for people with active generalized vitiligo covering more than 5% of their body (not counting hands and feet). It also looks at a protein in the blood called s100B to see how it relates to the condition and treatment response.
This study tests a new drug (BG-A3004) for safety in healthy volunteers and people with certain skin conditions like alopecia areata, cutaneous lichen planus, or vitiligo. It helps find out if the drug is safe and how the body processes it.
This trial tests an investigational drug called ICP-332 for vitiligo that isn't limited to one area (non-segmental). It aims to see if the drug can help restore skin color. The study is for both adults and teenagers who have had vitiligo for at least 3 months with a certain amount of skin affected.
This study tests a new drug called EI-001 for people with non-segmental vitiligo (a type where white patches appear on both sides of the body). It is for those whose vitiligo has not gotten better with standard treatments like creams or light therapy, or who cannot use those treatments.
Hear when a new Severe Alopecia Areata trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.